SCHEMBL3635809

SCHEMBL3635809

Cn1c(-c2cnc(Nc3ccc(Cl)cc3)c(Cl)c2)nc2ccccc21

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 12/20 0.76
KDR P35968 3/20 0.56
PTK2 Q05397 3/20 0.56
AKT1 P31749 1/20 0.56
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
NPC1 O15118 2/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PLK1 P53350 1/20 0.46
AURKB Q96GD4 1/20 0.46
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3637525 0.87 GRM5 (0.61) GRM5KDRPTK2AKT1MEN1
SCHEMBL3634023 0.87 GRM5 (0.59) GRM5KDRPTK2AKT1NPC1
SCHEMBL3635677 0.86 GRM5 (1.00) GRM5KDRPTK2AKT1MAPT
SCHEMBL3634663 0.86 GRM5 (0.85) GRM5MEN1KMT2ANPC1TP53
SCHEMBL3630048 0.86 GRM5 (0.68) GRM5KDRPTK2AKT1MEN1
SCHEMBL3635380 0.84 GRM5 (0.89) GRM5NPC1TP53MAPTSMN1; SMN2
SCHEMBL3635144 0.83 GRM5 (0.82) GRM5MAPTLMNAKDM4EALDH1A1
SCHEMBL3636002 0.80 GRM5 (0.72) GRM5MAPTALDH1A1
SCHEMBL3637910 0.80 GRM5 (0.89) GRM5MEN1KMT2ATP53MAPT
SCHEMBL3635975 0.79 GRM5 (0.88) GRM5TP53MAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146969-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Novartis Ag (CH) 2010-01-27 EP disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
US-20090105266-A1 Organic compounds NOVARTIS AG (CH) 2009-04-23 US disclosed
WO-2008128968-A1 NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 NOVARTIS AG (CH) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105266-A1 Organic compounds SLCO2B1, SLCO1B1, SLCO1B3 GRM5 4545/4885KDR 4616/4885PTK2 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.